California Stem Cell (CSC) is focused on the application of high-purity human cells in developing life changing therapies, including a platform cancer technology which has been approved to enter Phase III clinical trials, with Special Protocol Assessment (SPA) and Fast Track designation, in metastatic melanoma.
Since its founding in 2005, CSC has developed proprietary methods for the scalable production of high-purity human stem cells and their derivates. The ability to generate these cell types at high-purity in large quantities has put CSC in the unique position to address critical unmet needs in the development of life-changing therapies. CSC is currently conducting clinical trials investigating its patient specific cancer immunotherapy, a platform technology in development as a treatment for a broad range of cancers. The Company is also advancing several pipeline programs, including pre-clinical therapies for the treatment of spinal muscular atrophy (SMA), amyotrophic lateral sclerosis (ALS, or Lou Gehrig’s Disease), and spinal cord injury.
Single platform cancer therapy for the treatment of solid tumor cancers.Read More